Clinical and microbiological characteristics of bloodstream infections due to AmpC β-lactamase producing Enterobacteriaceae: An active surveillance cohort in a large centralized Canadian region

BMC Infectious Diseases

Volumn 14, Issue 1, 2014, Pages

  Chaubey, Vikas P ^a,e   Pitout, Johann D ^b,c   Dalton, Bruce ^a,d   Gregson, Daniel B ^a,b,c   Ross, Terry ^c   Laupland, Kevin B ^a,b  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c CALGARY LABORATORY SERVICES   (Canada)

^d FOOTHILLS HOSPITAL   (Canada)

^e W21C Research Centre   (Canada)

Author keywords

Bacteremia; Beta lactamases; Enterobacteriaceae

Indexed keywords

BETA LACTAMASE AMPC; CEPHALOSPORIN DERIVATIVE; OXYIMINOCEPHALOSPORIN DERIVATIVE; PIPERACILLIN PLUS TAZOBACTAM; QUINOLONE DERIVATIVE; UNCLASSIFIED DRUG; AMPC BETA-LACTAMASES; ANTIINFECTIVE AGENT; BACTERIAL PROTEIN; BETA LACTAM; BETA LACTAMASE;

ADULT; AGED; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; BLOODSTREAM INFECTION; CANADA; CITROBACTER; CLINICAL FEATURE; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DISEASE SURVEILLANCE; ENTEROBACTER; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ENTEROBACTERIACEAE; FEMALE; HAFNIA ALVEI; HUMAN; MAJOR CLINICAL STUDY; MALE; MORGANELLA MORGANII; MORTALITY; NONHUMAN; PROVIDENCIA; SERRATIA; THERAPY DELAY; BACTEREMIA; BIOSYNTHESIS; CROSS INFECTION; DRUG EFFECTS; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; ENZYMOLOGY; HEALTH SURVEY; ISOLATION AND PURIFICATION; METABOLISM; MICROBIOLOGY; MIDDLE AGED;

ADULT; AGED; ALBERTA; ANTI-BACTERIAL AGENTS; BACTEREMIA; BACTERIAL PROTEINS; BETA-LACTAMASES; BETA-LACTAMS; COHORT STUDIES; CROSS INFECTION; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; POPULATION SURVEILLANCE;

EID: 84924282914     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/s12879-014-0647-4     Document Type: Article

References (37)

1. Jacoby GA, Munoz-Price LS: The new beta-lactamases. N Engl J Med 2005, 352(4):380-391.
2. Philippon A, Arlet G, Jacoby GA: Plasmid-determined AmpC-type beta-lactamases. Antimicrob Agents Chemother 2002, 46(1):1-11.
3. Mulvey MR, Bryce E, Boyd DA, Ofner-Agostini M, Land AM, Simor AE, Paton S: Molecular characterization of cefoxitin-resistant Escherichia coli from Canadian hospitals. Antimicrob Agents Chemother 2005, 49(1):358-365.
4. Goldstein FW: Cephalosporinase induction and cephalosporin resistance: a longstanding misinterpretation. Clin Microbiol Infect 2002, 8(12):823-825.
5. Jacoby GA: AmpC beta-lactamases. Clinical microbiology reviews 2009, 22(1):161-182. Table of Contents.
6. Livermore DM, Brown DF, Quinn JP, Carmeli Y, Paterson DL, Yu VL: Should third-generation cephalosporins be avoided against AmpC-inducible Enterobacteriaceae? Clin Microbiol Infect 2004, 10(1):84-85.
7. Sanders WE Jr, Sanders CC: Inducible beta-lactamases: clinical and epidemiologic implications for use of newer cephalosporins. Rev Infect Dis 1988, 10(4):830-838.
8. Clinical and Laboratory Standards Institute: Performance Standards for Antimicrobial Susceptibility Testing; Twentieth Informational Supplement M100-S20. Wayne, PA: Clinical and Laboratory Standards Institute; 2010.
9. Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S, Suppes R, Feinstein D, Zanotti S, Taiberg L, Gurka D, Kumar A, Cheang M: Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006, 34(6):1589-1596.
10. Chow JW, Fine MJ, Shlaes DM, Quinn JP, Hooper DC, Johnson MP, Ramphal R, Wagener MM, Miyashiro DK, Yu VL: Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy. Ann Intern Med 1991, 115(8):585-590.
11. Kaye KS, Cosgrove S, Harris A, Eliopoulos GM, Carmeli Y: Risk factors for emergence of resistance to broad-spectrum cephalosporins among Enterobacter spp. Antimicrob Agents Chemother 2001, 45(9):2628-2630.
12. Cosgrove SE, Kaye KS, Eliopoulous GM, Carmeli Y: Health and economic outcomes of the emergence of third-generation cephalosporin resistance in Enterobacter species. Arch Intern Med 2002, 162(2):185-190.
13. Choi SH, Lee JE, Park SJ, Choi SH, Lee SO, Jeong JY, Kim MN, Woo JH, Kim YS: Emergence of antibiotic resistance during therapy for infections caused by Enterobacteriaceae producing AmpC beta-lactamase: implications for antibiotic use. Antimicrob Agents Chemother 2008, 52(3):995-1000.
14. Olson B, Weinstein RA, Nathan C, Kabins SA: Broad-spectrum beta-lactam resistance in Enterobacter: emergence during treatment and mechanisms of resistance. J Antimicrob Chemother 1983, 11(4):299-310.
15. Leal J, Gregson DB, Ross T, Flemons WW, Church DL, Laupland KB: Development of a novel electronic surveillance system for monitoring of bloodstream infections. Infect Control Hosp Epidemiol 2010, 31(7):740-747.
16. Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC, Saunders LD, Beck CA, Feasby TE, Ghali WA: Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 2005, 43(11):1130-1139.
17. Sundararajan V, Quan H, Halfon P, Fushimi K, Luthi JC, Burnand B, Ghali WA, International Methodology Consortium for Coded Health I: Cross-national comparative performance of three versions of the ICD-10 Charlson index. Med Care 2007, 45(12):1210-1215.
18. Laupland KB, Gregson DB, Church DL, Ross T, Pitout JD: Incidence, risk factors and outcomes of Escherichia coli bloodstream infections in a large Canadian region. Clin Microbiol Infect 2008, 14(11):1041-1047.
19. Pitout JD, Le PG, Moore KL, Church DL, Gregson DB: Detection of AmpC beta-lactamases in Escherichia coli, Klebsiella spp., Salmonella spp. and Proteus mirabilis in a regional clinical microbiology laboratory. Clin Microbiol Infect 2010, 16(2):165-170.
20. Pfaller MA, Jones RN, Marshall SA, Coffman SL, Hollis RJ, Edmond MB, Wenzel RP: Inducible amp C beta-lactamase producing gram-negative bacilli from blood stream infections: frequency, antimicrobial susceptibility, and molecular epidemiology in a national surveillance program (SCOPE). Diagn Microbiol Infect Dis 1997, 28(4):211-219.
21. Kim BN, Lee SO, Choi SH, Kim NJ, Woo JH, Ryu J, Kim YS: Outcome of antibiotic therapy for third-generation cephalosporin-resistant Gram-negative bacteraemia: an analysis of 249 cases caused by Citrobacter, Enterobacter and Serratia species. Int J Antimicrob Agents 2003, 22(2):106-111.
22. Deal EN, Micek ST, Ritchie DJ, Reichley RM, Dunne WM Jr, Kollef MH: Predictors of in-hospital mortality for bloodstream infections caused by Enterobacter species or Citrobacter freundii. Pharmacotherapy 2007, 27(2):191-199.
23. Cheong HS, Ko KS, Kang CI, Chung DR, Peck KR, Song JH: Clinical significance of infections caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae blood isolates with inducible AmpC beta-lactamase. Microb Drug Resist 2012, 18(4):446-452.
24. Choi SH, Kim YS, Chung JW, Kim TH, Choo EJ, Kim MN, Kim BN, Kim NJ, Woo JH, Ryu J: Serratia bacteremia in a large university hospital: trends in antibiotic resistance during 10 years and implications for antibiotic use. Infect Control Hosp Epidemiol 2002, 23(12):740-747.
25. Kang CI, Kim SH, Park WB, Lee KD, Kim HB, Oh MD, Kim EC, Choe KW: Bloodstream infections caused by Enterobacter species: predictors of 30-day mortality rate and impact of broad-spectrum cephalosporin resistance on outcome. Clin Infect Dis 2004, 39(6):812-818.
26. Lee IK, Liu JW: Clinical characteristics and risk factors for mortality in Morganella morganii bacteremia. J Microbiol Immunol Infect 2006, 39(4):328-334.
27. Lin YC, Chen TL, Ju HL, Chen HS, Wang FD, Yu KW, Liu CY: Clinical characteristics and risk factors for attributable mortality in Enterobacter cloacae bacteremia. J Microbiol Immunol Infect 2006, 39(1):67-72.
28. Liu CP, Wang NY, Lee CM, Weng LC, Tseng HK, Liu CW, Chiang CS, Huang FY: Nosocomial and community-acquired Enterobacter cloacae bloodstream infection: risk factors for and prevalence of SHV-12 in multiresistant isolates in a medical centre. J Hosp Infect 2004, 58(1):63-77.
29. Shih HI, Lee HC, Lee NY, Chang CM, Wu CJ, Wang LR, Ko NY, Ko WC: Serratia marcescens bacteremia at a medical center in southern Taiwan: high prevalence of cefotaxime resistance. J Microbiol Immunol Infect 2005, 38(5):350-357.
30. Laupland KB, Gregson DB, Zygun DA, Doig CJ, Mortis G, Church DL: Severe bloodstream infections: a population-based assessment. Crit Care Med 2004, 32(4):992-997.
31. Lodise TP, McKinnon PS, Swiderski L, Rybak MJ: Outcomes analysis of delayed antibiotic treatment for hospital-acquired Staphylococcus aureus bacteremia. Clin Infect Dis 2003, 36(11):1418-1423.
32. Schramm GE, Johnson JA, Doherty JA, Micek ST, Kollef MH: Methicillin-resistant staphylococcus aureus sterile-site infection: the importance of appropriate initial antimicrobial treatment. Crit Care Med 2006, 34(8):2069-2074.
33. Kim SH, Park WB, Lee KD, Kang CI, Bang JW, Kim HB, Kim EC, Oh MD, Choe KW: Outcome of inappropriate initial antimicrobial treatment in patients with methicillin-resistant Staphylococcus aureus bacteraemia. J Antimicrob Chemother 2004, 54(2):489-497.
34. Laupland KB, Church DL, Mucenski M, Sutherland LR, Davies HD: Population-based study of the epidemiology of and the risk factors for invasive Staphylococcus aureus infections. J Infect Dis 2003, 187(9):1452-1459.
35. Lin MY, Weinstein RA, Hota B: Delay of active antimicrobial therapy and mortality among patients with bacteremia: impact of severe neutropenia. Antimicrob Agents Chemother 2008, 52(9):3188-3194.
36. Scarsi KK, Feinglass JM, Scheetz MH, Postelnick MJ, Bolon MK, Noskin GA: Impact of inactive empiric antimicrobial therapy on inpatient mortality and length of stay. Antimicrob Agents Chemother 2006, 50(10):3355-3360.
37. Tabah A, Koulenti D, Laupland K, Misset B, Valles J, BruzzideCarvalho F, Paiva JA, Cakar N, Ma X, Eggimann P, Antonelli M, Bonten MJ, Csomos A, Krueger WA, Mikstacki A, Lipman J, Depuydt P, Vesin A, Garrouste-Orgeas M, Zahar JR, Blot S, Carlet J, Brun-Buisson C, Martin C, Rello J, Dimopoulos G, Timsit JF: Characteristics and determinants of outcome of hospital-acquired bloodstream infections in intensive care units: the EUROBACT International Cohort Study. Intensive Care Med 2012, 38(12):1930-1945.